Sector Expert: Echo He

Image: Echo He

Echo He, M.D., Ph.D., is a former senior vice president and senior analyst with the Maxim Group. Prior to joining Maxim, she was a director at Oppenheimer & Co. Inc., where she conducted equity analysis of small- to mid-cap U.S.-listed Chinese stocks. Dr. He also served as a vice president at CRT Capital Group LLC, where she conducted equity and credit analysis of Chinese small-cap, U.S.-based life science and distressed companies. Dr. He was a research scientist at the National Institutes of Health (NIH), where she conducted a part of the Human Genome Project, aimed at interpreting diseases and their risks by genetic patterns. Dr. He received a medical doctorate from Beijing University, a doctorate in medical sciences from the University of Toledo and a master's of business administration in finance and economics from the University of Chicago.



Recent Interviews

Two Cancer Stocks Take Shots on Goal: Echo He (6/19/14)

Oncology is king in biotech. Patients must be put on one drug, and then another, followed by another, as the disease progresses and becomes resistant. Multiple drugs will always be necessary, meaning multiple opportunities for drug companies. In this interview with The Life Sciences Report, analyst Echo He, formerly with the Maxim Group, serves investors two cancer drug picks that have been battered but are hot for a comeback.

Two Companies Follow Unmet Needs to Biotech Profits: Echo He (1/30/14)

Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they are diagnosed. In this interview with The Life Sciences Report, Echo He of the Maxim Group discusses her focus on how patients with unmet needs might ultimately get a fighting chance. To that end, she has selected two names that could produce both welcome cures and stunning share price results for investors who understand the value proposition of last-resort therapies.

Investing in Cancer Research Is Worth the Risk: Echo He (5/23/13)

drugdiscovery8If investigators could find a way to make breast cancer survivors truly cancer free, and if a diagnosis of pancreatic cancer were less dire, investors could reap windfalls while patients and their families rejoice. In this interview with The Life Sciences Report, Maxim Group Senior Equity Analyst Echo He brings two important names to the table and explains why she believes the potential upside is worth the risk.

Recent Quotes

"THLD's preliminary multiple myeloma data may lead to an expanded trial."

— Echo He, Maxim Group (6/3/14)
more >

"ARNI made significant progress on the clinical development of its lead drug, onapristone.

— Echo He, Maxim Group (5/9/14)
more >

"One catalyst for RNN might be a partnership with a big pharma on its two oral compounds in phase 1."

The Life Sciences Report Interview with Echo He (1/30/14)
more >

"CPRX's Firdapse has both orphan drug status and breakthrough designation."

The Life Sciences Report Interview with Echo He (1/30/14)
more >

"ARNI's collaboration with Leica Biosystems serves as a validation to onapristone's scientific foundation and development operations."

— Echo He, Maxim Group (1/22/14)
more >

"We believe CPRX's Firdapse clinical program, pathway and commercial plan are both sound and viable."

— Echo He, Maxim Group (10/18/13)
more >

"We are initiating coverage of CPRX with a Buy rating."

— Echo He, Maxim Group (9/24/13)
more >

"GALE's long term, risk reward profile is favorable."

— Echo He, Maxim Group (6/12/13)
more >



Due to permission requirements, not all quotes are shown.